MBX Biosciences, Inc. (NYSE:MBX - Get Free Report) shares gapped down prior to trading on Tuesday . The stock had previously closed at $16.28, but opened at $15.75. MBX Biosciences shares last traded at $15.76, with a volume of 36,026 shares trading hands.
Analyst Upgrades and Downgrades
A number of brokerages recently commented on MBX. Guggenheim began coverage on shares of MBX Biosciences in a research note on Tuesday, October 8th. They set a "buy" rating and a $44.00 price target on the stock. Jefferies Financial Group initiated coverage on MBX Biosciences in a research report on Tuesday, October 8th. They set a "buy" rating and a $35.00 target price on the stock. Stifel Nicolaus initiated coverage on MBX Biosciences in a research note on Tuesday, October 8th. They set a "buy" rating and a $40.00 price objective on the stock. Finally, JPMorgan Chase & Co. assumed coverage on MBX Biosciences in a research note on Tuesday, October 8th. They issued an "overweight" rating and a $30.00 target price for the company.
Get Our Latest Stock Analysis on MBX
MBX Biosciences Trading Down 10.3 %
The company's 50-day simple moving average is $20.23.
MBX Biosciences (NYSE:MBX - Get Free Report) last announced its quarterly earnings data on Thursday, November 7th. The company reported ($2.78) earnings per share for the quarter, missing analysts' consensus estimates of ($2.72) by ($0.06). As a group, analysts forecast that MBX Biosciences, Inc. will post -13.21 EPS for the current year.
Institutional Trading of MBX Biosciences
Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Point72 Asia Singapore Pte. Ltd. bought a new stake in MBX Biosciences during the 3rd quarter valued at approximately $278,000. Point72 Asset Management L.P. purchased a new stake in MBX Biosciences during the 3rd quarter valued at about $405,000. Barclays PLC purchased a new stake in shares of MBX Biosciences during the third quarter valued at approximately $426,000. Geode Capital Management LLC bought a new stake in shares of MBX Biosciences in the 3rd quarter worth $579,000. Finally, Point72 DIFC Ltd bought a new position in shares of MBX Biosciences during the third quarter valued at $624,000.
About MBX Biosciences
(
Get Free Report)
MBX Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism.
Featured Stories
Before you consider MBX Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MBX Biosciences wasn't on the list.
While MBX Biosciences currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
